Anji Kanger received 15 million angel round financing, Danhua Capital led

Medical Valley today (November 29) news, Anji Kanger (Shenzhen) Technology Co., Ltd. (hereinafter referred to as "Anji Kanger") has received 15 million RMB angel round financing, led by Danhua Capital (DHVC), and alliance Venture capital and investment.

Founded in early 2017, Anji Kanger is headquartered in Nanshan District Science and Technology Park in Shenzhen. It has R&D centers in Silicon Valley and Pittsburgh, USA. It is dedicated to creating an artificial intelligence medical platform based on genomic data and combining various clinical medical data. Patients and doctors provide clinically accurate decision aids. Anji Kanger brings genomic big data and artificial intelligence to mainstream medical practice, and the intelligent sequencing service system developed completes all service processes from sampling to report interpretation within three weeks.

The founding team of the company is from the Department of Biomedical Engineering of Peking University, the Department of Computer Science of Tsinghua University, the Department of Biology of the Chinese University of Science and Technology, the Academy of Military Medical Sciences, the Department of Biomedical Engineering of the University of Illinois at Urbana-Champaign, and the Department of Computer Science of Carnegie Mellon University. He has more than ten years of bioinformatics, high-throughput sequencing, clinical genetics and artificial intelligence academic and industry experience.

Unlike most current cancer-focused clinical tests, NIPT, and health management based on NGS, Anji Kanger focuses on the field of genetic diseases. At present, some genetic diseases cannot be interfered and controlled after the onset of illness. Li Yang revealed that their next goal is to achieve screening of healthy people, especially newborns.

Zhang Dadi, the managing partner of Danhua Capital China, said: "The genetic industry is currently full of opportunities and vitality. Genetic testing will not only play an irreplaceable role in disease prevention and medication guidance, but genetic testing will become a resident. Standard testing. Gene detection new and old technology In the rapid iteration, the strong professional background, technical strength and rapid execution of the Anji Kanger team are very suitable for this challenge."

Disposable Negative Pressure Drainage Device

Changzhou Weipu Medical Devices Co., Ltd. , https://www.cnweipumedical.com